Targeting Influenza A Virus RNA Promoter

Chem Biol Drug Des. 2015 Oct;86(4):663-73. doi: 10.1111/cbdd.12534. Epub 2015 Mar 13.

Abstract

The emergence of drug-resistant strains of influenza virus makes exploring new classes of inhibitors that target universally conserved viral targets a highly important goal. The influenza A viral genome is made up of eight single-stranded RNA-negative segments. The RNA promoter, consisting of the conserved sequences at the 3' and 5' end of each RNA genomic segment, is universally conserved among influenza A virus strains and in all segments. Previously, we reported on the identification and NMR structure of DPQ (6,7-dimethoxy-2-(1-piperazinyl)-4-quinazolinamine) (compound 1) in complex with the RNA promoter. Here, we report on additional screening and SAR studies with compound 1, including ex vivo anti-influenza activity assays, resulted in improved cellular activity against influenza A virus in the micromolar range.

Keywords: chemical biology; drug design; drug discovery.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antiviral Agents / chemistry*
  • Antiviral Agents / pharmacology*
  • Dogs
  • Drug Evaluation, Preclinical / methods
  • Influenza A virus / drug effects
  • Influenza A virus / genetics*
  • Madin Darby Canine Kidney Cells / drug effects
  • Madin Darby Canine Kidney Cells / virology
  • Magnetic Resonance Spectroscopy
  • Molecular Structure
  • Peptide Library
  • Piperazines / chemistry
  • Piperazines / pharmacology*
  • Promoter Regions, Genetic*
  • Quinazolines / chemistry
  • Quinazolines / pharmacology*
  • RNA, Viral / drug effects*
  • Structure-Activity Relationship
  • Virus Replication / drug effects

Substances

  • 6,7-dimethoxy-2-(1-piperazinyl)-4-quinazolinamine
  • Antiviral Agents
  • Peptide Library
  • Piperazines
  • Quinazolines
  • RNA, Viral